Advice

following an abbreviated submission:

leuprorelin acetate (Prostap®) is accepted for use within NHSScotland.

Indication under review: as treatment in pre- and perimenopausal women with advanced breast cancer suitable for hormonal manipulation.

Leuprorelin offers an additional treatment choice in the therapeutic class of gonadotropin-releasing hormone (GnRH) analogues for this indication.

Download detailed advice722KB (PDF)

Download

Medicine details

Medicine name:
leuprorelin acetate (Prostap DCS)
SMC ID:
SMC2320
Indication:

As treatment in pre- and perimenopausal women with advanced breast cancer suitable for hormonal manipulation.

Pharmaceutical company
Takeda UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Abbreviated
Status
Accepted
Date advice published
08 February 2021